LSTA:NASDAQ, Lisata Therapeutics, Inc.

Why LSTA stock rose on November 11

Lisata Therapeutics, Inc. rose 17.6% on Wednesday, November 11, 2026, on 1,061,400 shares, 3.5 times its average daily volume. No headline about LSTA came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

LSTA stock overview

Lisata Therapeutics, Inc. (LSTA:NASDAQ) closed at $1.09 on November 16, 2026, down 9.92% on the day. The stock trades 78.5% below its 52-week high of $5.07 and 13.5% above its 52-week low of $0.960. Over the past year, it lost 46.8%. Lisata Therapeutics, Inc. is part of the Health Care sector.

Key figures

Price
$1.09
Day change
-9.92%
Volume
44,892
Average volume
304,417
Market cap
11M+
52-week range
$0.960 – $5.07
50-day average
$1.28
200-day average
$2.86

Price action over the past year

In 252 trading sessions since November 14, 2025, LSTA closed higher on 95 days (38%). Its best day was January 21, 2026 (+86.57%) and its worst was July 21, 2026 (-36.54%). The stock moved 10% or more in a single session 23 times. It opened at least 5% above the previous day's high 5 times.

Recent signals

LSTA news

About Lisata Therapeutics, Inc.

Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its current product candidates include XOWNA, HONEDRA and CLBS201.

Similar stocks

Find more stocks like LSTA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.